DENTSPLY SIRONA (XRAY) Releases FY18 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) issued an update on its FY18 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $2.00-2.15 for the period, compared to the Thomson Reuters consensus estimate of $2.07. DENTSPLY SIRONA also updated its FY 2018 guidance to $2.00 EPS.

NASDAQ XRAY traded down $0.74 during trading hours on Friday, reaching $36.06. 8,501,655 shares of the company were exchanged, compared to its average volume of 2,934,481. DENTSPLY SIRONA has a 1 year low of $33.93 and a 1 year high of $68.98. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.10 and a current ratio of 1.69. The company has a market capitalization of $8.12 billion, a PE ratio of 14.21, a price-to-earnings-growth ratio of 2.12 and a beta of 1.15.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Thursday, November 8th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.08). DENTSPLY SIRONA had a positive return on equity of 9.12% and a negative net margin of 39.62%. The company had revenue of $928.40 million for the quarter, compared to analysts’ expectations of $951.58 million. During the same quarter last year, the business posted $0.70 EPS. The business’s quarterly revenue was down 8.0% on a year-over-year basis. As a group, analysts forecast that DENTSPLY SIRONA will post 2.07 EPS for the current fiscal year.

Several research firms have recently weighed in on XRAY. ValuEngine downgraded shares of DENTSPLY SIRONA from a sell rating to a strong sell rating in a research note on Tuesday, September 4th. BidaskClub downgraded shares of DENTSPLY SIRONA from a hold rating to a sell rating in a research note on Thursday, September 27th. Zacks Investment Research downgraded shares of DENTSPLY SIRONA from a hold rating to a sell rating in a research note on Monday, August 6th. Stephens downgraded shares of DENTSPLY SIRONA from an overweight rating to an equal weight rating and set a $75.00 target price for the company. in a research note on Wednesday, August 8th. Finally, TheStreet downgraded shares of DENTSPLY SIRONA from a c- rating to a d+ rating in a research note on Tuesday, August 14th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company’s stock. DENTSPLY SIRONA has an average rating of Hold and an average target price of $51.50.

TRADEMARK VIOLATION NOTICE: “DENTSPLY SIRONA (XRAY) Releases FY18 Earnings Guidance” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://transcriptdaily.com/2018/11/10/dentsply-sirona-xray-releases-fy18-earnings-guidance.html.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Featured Story: What is Cost of Debt?

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply